Skip to main content
JAMA Network logoLink to JAMA Network
. 2017 Sep 14;3(9):1286. doi: 10.1001/jamaoncol.2017.3416

Error in Figure

PMCID: PMC6325963  PMID: 28910457

In the Original Investigation titled “Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Final Results of a Phase 2 Study,”1 published online July 20, 2017, there were errors in Figure 2a in the numbers at risk at 24, 48, 72, and 96 months. The correct numbers at risk are as follows: for overall survival, 36, 17, 11, and 2, and for progression-free survival, 21, 13, 8, and 1, respectively. This article was corrected online.

Reference

  • 1.Chang JY, Verma V, Li M, et al. . Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non–small cell lung cancer: final results of a phase 2 study. JAMA Oncol. 2017;3(8):e172032. doi: 10.1001/jamaoncol.2017.2032 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Oncology are provided here courtesy of American Medical Association

RESOURCES